News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Aesica Appoints Two New Business Development Managers Strategic Drive Aimed at Further Revenues Growth in Europe

7/15/2013 6:38:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

15 July 2013 – Monheim and Queenborough: Aesica, the global contract development and manufacturing organisation (CDMO), has appointed Sven Thomas and David Ross as business development managers. Their appointment is the next phase in the company’s international drive to increase sales from its integrated API, formulation development and manufacturing services and they will be responsible for ensuring potential customers are clearly aware of how the company can support their manufacturing and development needs.

Under the new structure, David Ross will focus on the UK, Ireland and Scandinavia whilst Sven Thomas will handle Central and Eastern Europe with a strong emphasis on expanding the level of business from Germany and the growing economies in Eastern Europe. In combination, three business development managers, Nicholas Micheaud, who has responsibility for South Western Europe, David Ross and Sven Thomas report to Jeremy Drummond, the Sales Director. Sven Thomas brings a breadth of pharmaceutical manufacturing expertise to the task in hand having previously worked for UCB, whilst David Ross brings wide ranging experience in contract research and contract manufacturing with Patheon, Catalant and Ipsen.

Sven Thomas commented: “I am delighted to take on my new position at Aesica and to play a key role in driving forward our services in the German market, as well as Eastern Europe. Indeed, the fact that we have site facilities geographically situated in Monheim and Zwickau as well as in Italy and the UK, ensures that Aesica is well situated to deliver reliable services to customers from all of Europe.”

He continued: “Moreover, we have a strong pedigree in Germany with over thirty years manufacturing, working on established UCB and Schwarz products at our Zwickau and Monheim sites. We provide a bespoke individualised approach to client servicing and have the flexibility to cater for what are often multiple formulated product needs of each customer.”

David Ross remarked: “I very much look forward to playing a key regional role in driving new business across the UK, Ireland and Scandinavia. The integrated nature, scale and range of our service offering and our track record of transferring in new technologies stand us out in the highly competitive CDMO market place”.

About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

• Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.

• The company currently employs approximately 1,300 people.

• In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.

• The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.

For media enquiries, please contact Alex Heeley or Tristan Jervis at De Facto Communications on: +44 (0) 20 7203 6740 or e-mail;

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus